Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm

By sjmartinez • December 20, 2024

De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM, Tian H, Watts JM. Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm. Br J Haematol. 2024 Dec 19. doi: 10.1111/bjh.19944. Epub ahead of print. PMID: 39701584.

Tags: acute myeloid leukaemia, blast‐phase myeloproliferative neoplasm, Hematology/Oncology, IDH1 mutation, myeloproliferative neoplasms, Publications

A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That Evolved From Myelodysplastic Neoplasm

Bansil S, Lai SY, Lo AE, Dietz R Jr, Reed JP. A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That[...]

PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma

Kumar S, Benavides-Serrato A, Saunders JT, Nishimura RN, Gera JF. PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma.[...]

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases

Juarez Casillas JE, Nezafat M, Benitez CM, Rzechowski K, Kane N, Sjöstrand K, Anand A, Sonni I, Berenji GR, Duriseti S, Rettig MB, Nickols NG.[...]